Zacks Research Brokers Reduce Earnings Estimates for Blueprint Medicines Co. (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Zacks Research lowered their Q2 2025 earnings per share estimates for Blueprint Medicines in a research report issued on Tuesday, June 18th. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings of ($0.87) per share for the quarter, down from their previous estimate of ($0.86). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.15) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q3 2025 earnings at ($0.73) EPS, FY2025 earnings at ($3.09) EPS and FY2026 earnings at ($0.64) EPS.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.32. The firm had revenue of $96.12 million for the quarter, compared to analysts’ expectations of $82.58 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%.

Several other analysts also recently commented on BPMC. The Goldman Sachs Group raised their price objective on shares of Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research report on Thursday, May 2nd. Wedbush reiterated an “outperform” rating and set a $110.00 target price on shares of Blueprint Medicines in a research report on Friday, April 26th. Stifel Nicolaus lifted their target price on Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Finally, Piper Sandler upped their price target on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.00.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC opened at $104.23 on Friday. The company has a market capitalization of $6.53 billion, a P/E ratio of -21.67 and a beta of 0.70. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $111.02. The firm’s 50 day simple moving average is $101.33 and its two-hundred day simple moving average is $91.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61.

Insider Buying and Selling

In other news, insider Percy H. Carter sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the transaction, the insider now owns 41,895 shares of the company’s stock, valued at $4,404,421.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider L. Becker Hewes sold 4,922 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $106.43, for a total transaction of $523,848.46. Following the completion of the sale, the insider now owns 31,938 shares of the company’s stock, valued at $3,399,161.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Percy H. Carter sold 4,000 shares of Blueprint Medicines stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the completion of the transaction, the insider now directly owns 41,895 shares in the company, valued at $4,404,421.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,864 shares of company stock valued at $6,272,263. Company insiders own 4.21% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BPMC. Price T Rowe Associates Inc. MD lifted its stake in shares of Blueprint Medicines by 15.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company’s stock worth $592,954,000 after buying an additional 821,868 shares during the period. Norges Bank purchased a new stake in Blueprint Medicines in the fourth quarter valued at approximately $55,893,000. Polar Capital Holdings Plc increased its holdings in Blueprint Medicines by 108.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company’s stock worth $52,229,000 after buying an additional 540,000 shares during the period. Rock Springs Capital Management LP raised its position in Blueprint Medicines by 22.8% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company’s stock worth $134,855,000 after buying an additional 498,622 shares during the last quarter. Finally, Avidity Partners Management LP lifted its stake in Blueprint Medicines by 81.1% during the 3rd quarter. Avidity Partners Management LP now owns 751,600 shares of the biotechnology company’s stock valued at $37,745,000 after acquiring an additional 336,600 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.